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Summary 
We describe here a new method for predicting class II major histocompatibility complex-binding 
peptides, based on the preferences observed in a systematic series of peptide binding experiments 
where each position in a "minimal" peptide was replaced individually by every amino acid. The 
DRBI*0401 peptide binding preferences were determined and incorporated into a computer program 
that looks through sequences for potential epitopes and assigns each a score. These scores correlate 
well with previously determined T  cell epitopes of foreign antigens and endogenous peptides 
from self proteins. Our findings hold implications for the design of subunit vaccines and in the 
identification of autoantigenic peptide regions within self proteins. 
M 
HC class II molecules are highly polymorphic proteins 
that bind peptides derived from processing of antigens 
and present them to T  cells (1). Methods to predict regions 
in protein sequences capable of binding to human MHC class 
II molecules would be very valuable for many immunolog- 
ical applications. A quantitative prediction of MHC binding 
sites,  however, requires the understanding of the rules gov- 
erning peptide--MHC class  II interaction. The use of M13 
peptide display libraries to identify aUele-specific motifs (2-4), 
together with structural analyses of HLA-DRl-peptide com- 
plexes (5, 6) provided the basis to predict MHC class II-pep- 
tide interaction: (a) the identification of precisely spaced an- 
chor positions in large HLA-DR-selected peptide pools and 
the x-ray crystallographic studies suggested an overall similar, 
sequence-independent peptide conformation (3,  5);  (b) the 
fact that the anchor at position 1 (pl) 1 was found obliga- 
tory for high affinity binding allowed us to define frames in 
HLA-DR bound peptides (4); (c) the position of a particular 
side chain, with respect to the pl-frame,'determines whether 
a given amino acid behaves as anchor residue, inhibitory res- 
idue, or residue neutral for binding (4).  This information 
led  us  to  develop  a  new  method  for  predicting  class  II 
MHC-binding peptides. The method is based on the hypoth- 
esis that peptide binding to HLA-DR  correlates with the 
net result of all side chain effects in any given peptide, and 
that most side chain effects depend on their relative position 
to the pl anchor, rather than on the remaining peptide se- 
1 Abbreviations used in this paper: HA,  haemagglutinin;  IC,  inhibitory 
concentration; MBP, myelin basic protein; pl, position 1. 
quence. Pl-anchored designer peptide libraries were thus used 
for scanning the relative peptide positions 2-9 for the effects 
of each amino acid side chain on binding to the human class 
II molecule DRBI*0401. When values, individually obtained 
by side chain scanning, were assigned to the amino acid residues 
of the selected protein region, the sum of these values cor- 
related with the MHC-binding affinity of the respective pep- 
tide. The processing of the side chain scanning data into a 
software  allowed a rapid  and nearly perfect prediction of 
DRBI*0401  binding regions in any protein sequence. 
Materials and Methods 
Preparation of HLA-DRBI*0401 Molecules.  DRBI*0401  mole- 
cules were isolated from human lymphoblastoid cell lines BSM and 
PREISS as described (7). 
Peptide Synthesis.  Pl-anchored designer peptide libraries were 
synthesized with multiple peptide synthesizers (models 350 and 
396; Advanced ChemTech, Louisville, KY) using Fmoc chemistry. 
Double and triple coupling procedures and at least a 10-fold surplus 
of Fmoc amino acids as compared with the free NH2 termini of 
the resin were used to minimize the production of deletion mu- 
tants.  Peptides were analyzed by analytical reverse-phase HPLC. 
Peptides used in this study were routinely >~75% pure. 
Highflux DR-peptide  Binding  Assay.  Peptides were dissolved in 
DMSO to a final concentration of 2 mM and 50/~1 of each peptide 
was transferred into the A-row wells of 96-well plates (dilution 
plates). 50 #1 of PBS was added to the A-row wells and 180 #1 
of PBS/DMSO (1:1) to the B-F row wells of the dilution plates. 
Peptides were simultaneously diluted by serially transferring 20 #1 
from row A to row F. 10/~1 of each well of the dilution plate was 
transferred to the corresponding wells of a second set of 96-well 
plates (binding plates). 30 #1 of mix 1 (500 ng/m112SI-labeled  Flu 
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mix 2 (30/zg/ml affinity-purified DRBI*0401 antigen in 1% NP- 
40; I mM PMSF; 1 mM EDTA; 10/~g/ml of each of the following 
protease inhibitors: soybean trypsin inhibitor, antipain, pepstatin, 
leupeptin, and chymostatin; 0.15 M NaC1; and 50-100 mM citrate- 
phosphate buffer, pH 7) were added to each well of the binding 
plates and incubated for 24 h at room temperature. 30/~1 of mix 
3 (150/zg/ml biotinylated anti-DR antibody in PBS) was added 
and incubated for another 3 h at room temperature. 200/zl of BSA- 
blocked streptavidin on 4% beaded agarose was added into each 
tube (row A to F) of cluster tube racks. 70/~t of each well from 
the binding plate was transferred to the corresponding tubes of 
the cluster tube racks and incubated for 10 min. The streptavidin 
solid phase was simultaneously washed four times with PBS using 
specifically constructed devices (8). The tubes were directly counted 
in a gamma counter. The high-flux peptide binding assay permitted 
the processing ofa pl-anchored designer peptide library within 2 d. 
This corresponds to 960 single assays using six dilutions for each 
peptide. 
Prediction of HLA-DRBI*0401  Binding Regions.  The inhibitory 
concentration (IC)s0 data derived from side chain scanning of pl- 
anchored designer libraries  were processed as follows.  The ICs0 
data were normalized by dividing them by the ICs0 values obtained 
from the Ala-substitutions. The reverse values of the normalized 
data were determined, and last, the logarithms (log) of the reverse 
values  were calculated.  These values  were directly incorporated 
in a simple prediction software, written with Microsoft QBasic 
for Macintosh  (8).  The  score  is  thus  the  sum of log  (ICs0-taJ 
ICs0-,,,id~0) for each residue,  minus 1 if Pl  is aliphatic. The "ali- 
phatic correction" reflects  the ,~10-fold lower binding affinity of 
designer peptides with aliphatic pl anchors as compared with pep- 
tides  with  aromatic pl-anchors (4). 
Results and Discussion 
X-ray crystallographic studies indicate that different pep- 
tides bind with a similar conformation to HLA-DR mole- 
cules (6). This observation is supported by the analysis of 
a  side chain scanning 
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Figure  1.  The principle of side chain scanning of pl-anchored designer 
peptide libraries. (a) Pl-anchoting of the peptide library: schematic  represen- 
tation. (b and c) Identification of position-specific positive and negative 
effects on DRBI*0401 binding by scanning with Glu (b) and Arg (c). 
The relative binding was determined as follows: the ICs0 data were nor- 
realized  by  dividing  them  by  the  ICs0 values obtained  from  Ala- 
substitutions. The logarithm of the reverse and normalized values were 
then determined. Zero indicates the Ala baseline, values below zero show 
inhibitory effects and values above zero anchor effects. 
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Figure  2.  Example  for the calcu- 
lation of the peptide scores. First, 
a given protein sequence is scanned 
for the DRBl*0401-specific, aro- 
matic pl-anchor residues Tyr, Phe, 
and Trp (3) or the aliphatic residues 
Leu, Met, Val, and lle (4). Next, 
position-specific and  side chain- 
specific  values individually obtained 
by side chain scanning (see Table 1) 
are then  assigned to  each of the 
amino acid residues of the selected, 
nine residue-long protein regions. 
The peptide score  is the sum of these 
values. The score of those selected 
regions with an aliphatic pl anchor 
is subtracted by 1, corresponding to 
an "~10-fold lower binding affinity 
of designer peptides with aliphatic 
pl anchors as compared with pep- 
tides with aromatic pl-anchors (4). 
2354  Predicting MHC Class II-Peptide Interaction with Side Chain Scanning the large number of peptide sequences selected from M13 
phage display libraries (2, 3). Although these peptides differ 
in their primary sequence, most of them share perfectly spaced 
anchor residues, suggesting an overall similar and sequence- 
independent peptide conformation. Experiments with designer 
peptides further support this hypothesis. Anchor and inhibi- 
tory residues lose their effect in different designer peptides 
if shifted by one position towards the NH2 or COOH ter- 
minus (4).  This indicates a low degree of flexibility in the 
peptide structure once bound to the MHC molecule and sug- 
gests that once all the peptide side chain effects are known, 
peptide-MHC class II interaction can be predicted. To vali- 
date this hypothesis we performed a quantitative analysis of 
the side chain effects  at each peptide position.  To enable a 
detailed analysis it was important to prevent potential shifts 
within the peptide frame, and to supply a sensitive peptide 
binding assay to accurately measure side chain effects. To meet 
these requirements we synthesized pl-anchored designer pep- 
tide libraries.  They consisted of short, pl-anchored and Ala- 
based designer peptides where all naturally occurring L-amino 
acids had been substituted at each position from 2 to 9 (Fig. 
1 a). Nine residue-long peptides cover most of the potential 
side chain interactions within the MHC cleft, and show re- 
duced main chain interaction compared with longer peptides 
(4, 6). The reduced length amplifies the effect of anchors and 
inhibitory residues and decreases the probability of shifts within 
the pl-frame. 
A typical side chain scanning of the two basic library pep- 
tides YASAAAAAA and YRSMAAAAA with Glu and Arg 
on the HLA-DRBI*0401 molecule is shown in Fig. 1, b-c. 
Although the two peptides differ in their ICso values "~ 100- 
fold, due to the two additional anchor residues within the 
latter (3, 4), the results of the side chain scanning were nearly 
identical,  supporting the concept of position-specific side chain 
effects independent  of the remaining  sequence. 
We next performed a side chain scanning of all natural amino 
acid residues (except CYS) at positions 2 to 9 of YASAAAAAA 
using a newly developed high-flux peptide binding assay as 
described in Materials and Methods.  The results shown in 
Table 1 revealed new position-specific positive and negative 
side chain effects in addition  to the anchor  residues previ- 
ously identified by phage library screening.  The logarithm 
of the normalized  and reverse ICs0 values derived from the 
side chain scanning were then processed into a simple com- 
puter algorithm (Fig. 2). The program first scans a given pro- 
tein  sequence  for  the  obligatory  DRBI*0401-pl  anchor 
residues.  After their identification, amino acid residues at rel- 
ative positions 2-9 are located.  Next,  values derived from 
the side chain scanning (Table 1) are assigned to each amino 
acid residue of the selected peptide or protein region.  The 
sum of these values is defined as "peptide score" Thus, the 
peptide score correlates directly with the biochemical data 
derived from the side chain  scanning.  If one assumes that 
the position-specific effects of amino acid side chains are in- 
dependent  of the remaining  peptide sequence,  the peptide 
score should in addition correlate with the binding affinity 
of the peptides and henceforth allow one to predict class II-pep- 
tide interaction. 
Table  1.  Results of the Side Chain Scanning on DRBI*0401 
with a pl-Anchored  Peptide Library 
pl  p2  p3  p4  p5  p6  p7  p8  p9 
A  -~  0  0  0  0  0  0 
D  -  -1.3 S -1.3  +1.7  -0.2  0  -1.1 
E  -  +0.1  -1.2  +0.8  -0.1  -1.2  -0.2 
F  0  +0.8  +0.8  -0.8  +0.3  -1.3  -0.8 
G  -  +0.5  +0.2  -1.5  -0.2  -1.1  -1.5 
H  -  +0.8  +0.2  +0.8  -0.1  -1.6  -0.8 
I  -1.0[[  +1.1  +1.5  +0.8  +0.1  -0.2  -0.2 
K  -  +1.1  0  -2.2  +0.3  -2.3  -1.2 
L  -1.0  +1.0  +1.0  -0.6  +0.1  -1.3  +0.4 
M  -1.0  +1.1  +1.4  +1.4  +0.3  -1.3  +0.7 
N  -  +0.8  +0.5  +0.5  +0.2  +1.7  -0.1 
P  --  -0.5  +0.3  -2.1  +0.5  +0.1  -0.3 
Q  -  +1.2  0  +1.1  +0.1  -1.2  -0.5 
Ik  -  +2.2  +0.7  -1.5  0  -2.2  -1.2 
S  -  -0.3  +0.2  +1.1  +0.4  +1.7  -0.4 
T  -  0  0  +0.8  +0.6  +1.9  -0.2 
V  -1.0  +2.1  +0.5  +0.5  +0.4  +1.3  +0.5 
W  0  -0.1  0  -1.2  -0.1  -0.9  -1.3 
Y  0  +0.9  +0.8  -1.0  -0.2  -1.1  -0.7 
0  0 
-1.1  -2.6 
-0.2  -1.8 
+0.1  -0.8 
-0.5  -0.2 
0  +0.3 
-0.1  -0.4 
+0.9  -0.9 
+0.6  -1.3 
+0.4  -0.4 
+0.7  -1.1 
-0.2  -1.6 
+1.6  +0.7 
+0.7  -0.9 
+0.6  + 1.2 
+0.5  -0.3 
+0.4  +0.5 
+0.6  -0.3 
+1.3  -1.5 
The peptide YASAAAAAA was used as basic library peptide. 
* The single letter code for amino acids is: A, Ala, D, Asp, E, Glu, F, 
Phe, G, Gly, H, His, I, Ile, K, Lys, L, Leu, M, Met, N, Asn, P, Pro, 
Q, Gin, R, Arg, S, Set, T, Thr, V, Val, W, Trp, and Y, Tyr. Cys- 
teines were  not included in the side chain scanning procedure. 
Dashes in the row  corresponding  to  position  1 indicate  that  only 
aliphatic or aromatic residues were considered as pl anchor (4). 
S Relative binding values were determined as in Fig.  1. 
II  -  1 values were arbitrarily assigned to aliphatic pl anchors. This cor- 
responds  to  an ~10-fold lower binding af~nity  of designer  peptides 
with aliphatic  pl  anchors  as  compared  with  peptides  with  aromatic 
pl-anchors (4). 
To validate our scoring system we first compared the dis- 
tribution of peptide scores in a DRBI*0401 phage-selected 
peptide pool (3) with the score distribution in a nonselected 
peptide pool (Fig.  3 a). Fig. 3 b shows a significant shift of 
the DRBl*0401-selected peptides towards higher scores. 85% 
of the selected peptides had scores higher than 2 as compared 
with only 13% of the nonselected peptides. Three peptides 
from the DRBl*0401-selected pool had a low score (Fig. 3 
b), and accordingly,  these peptides were unable to bind to 
DRBI*0401,  whereas  seven  out  of seven  peptides  tested 
having high  scores showed high affinity binding  (data not 
shown). 
To further evaluate the correlation between scores and pep- 
tide binding,  we next synthesized 48 nonamer and 56 thir- 
teenmer peptides derived from known protein sequences with 
scores ranging from  -5  to  + 5. As shown in Fig. 3, c and 
d, most peptides exhibited a correlation between scores and 
binding affinities to DRBI*0401. It is important to note that 
peptides with the highest affinities also had the highest scores 
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Figure 3.  Correlation between peptide score and 
peptide affinity. (a) Average distribution of peptide 
scores in human proteins. The scores of pl-anchored 
peptides derived from several  randomly chosen human 
proteins, corresponding to ",8,000 amino acid residues, 
has been calculated as described in Fig. 2. (b) Peptide 
scores for a DRBl*0401-selected  peptide pool. The 
peptides of DRB1 * 0401-selected bacteriophage (solid 
bars) show significantly  higher scores than the randomly 
selected, pl-anchored peptides (unfilled bars) shown in 
Fig. 4 a.  Only three  peptides of the DRBI*0401- 
selected phage pool had low scores (stippled bars). None 
of them bound to the DRBI* 0401 molecule (data not 
shown). (c) 48 nine-residue-long  peptides were selected 
from several  human proteins to cover the range of scores 
shown in Fig. 4 a. The scores of nearly all peptides 
correlated with their binding  affinity to D1LBI*0401 
molecules. Relative binding  values were derived from 
the reciprocal of the ICs0 of each peptide.  (d) The 
scores of 54 thirteenmer peptides derived from several 
human proteins correlated with their binding  affinity 
to DRB1*0401 molecules. If multiple  pl frames were 
found in the same peptide,  the highest  score was 
selected. P1 frames shorter than eight residues were 
not considered. 
(Fig. 3 d), demonstrating the usefulness of this method to 
predict human MHC  class  II-peptide interaction. 
It has so far been very difficult to predict with reasonable 
accuracy whether a particular peptide sequence will be able 
to bind to a particular mouse or human MHC molecule. Only 
very recently Reay et al.  (8a), by using a synthetic peptide 
library, have been able to identify a predicting motif for the 
IE  k molecule. Previous approaches based on sequence align- 
ments or simple class II peptide binding motifs allowed only 
for limited predictions of peptides with three and four residues 
in frame (4, 9-11). The binding of the vast majority of the 
peptides having only one or two anchor residues, however, 
could not be identified by these algorithms. The side chain 
scanning method is highly predictive. For the identification 
of DRBI*0401 binding regions it first selects all peptides with 
the obligatory pl-anchor residue, which account for as much 
as 30% of the possible nonamers in randomly chosen sequences 
(Fig. 3 a).  However, only ",~4% of all peptide frames have 
a score higher than 2, and even less bind with high affinity 
(Fig.  3, c and d).  This demonstrates a considerably higher 
stringency of DR.Bl*0401-peptide binding than expected on 
the basis  of previous DRBI*0401  motifs (3,  12). 
The ability to predict class II-peptide binding, based solely 
on data obtained from side chain scanning, suggests that the 
conformation of most class II bound peptides is independent 
of their primary structure. This is in accordance with recent 
structural data from Stern et al. (6), indicating that conserved 
hydrogen bonds between HLA-DRBI*0101 residues and the 
peptide main chain may provide a universal mode of peptide 
binding.  Although the scoring system seems to be highly 
predictive, we cannot exclude the possibility that in a few 
instances the peptide side chains might interact with one an- 
other, leading to changes within the conformation of the pep- 
tide. This could explain why the biochemical data of few of 
the peptides shown in Fig. 4, c and d did not conform to 
the predicted score. 
The pl-anchor residues have been shown to be necessary 
for high affinity peptide-binding for many HLA-DR mole- 
cules (4,  13-15).  The described procedure, therefore, seems 
applicable to many different HLA-DR molecules. In a few 
instances, however, peptides lacking the pl anchor have been 
shown to bind with low affinity (13). For a complete predic- 
tion, which also includes these particular cases,  it may be 
necessary to calculate the score for all peptide frames in a given 
protein. 
An obvious application is the identification of T cell epi- 
topes in natural polypeptides, Dominant T cell epitopes are 
often peptides that bind most avidly to MHC  molecules. 
Hence, the possibility to predict HLA-DR-peptide interac- 
tion should help define potential dominant epitopes in in- 
dividual proteins at high precision. For example, the scan- 
ning of the human myelin basic protein (MBP) molecule for 
regions with high peptide scores revealed a single peptide with 
a score higher than 2 (Fig. 4 a). This peptide (MBP 91-99) 
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belongs to a region of the MBP (MBP 87-106),  previously 
described as immunodominant  for the DRBl*0401-restricted 
T  call recognition  (16, 17). Similarly,  the region 309-317 of 
the influenza  HA molecule  shows  the highest  score of all 
possible HA peptides  (Fig.  4  b). This  peptide is known  as 
the immunodominant  T cell epitope of the HA molecule (18). 
Sequences  of naturally  processed  peptides,  eluted  from 
DtLBI*0401 molecules were recently determined by a com- 
bination of mass spectrometry and Edman microsequencing 
(19). The predominant endogenous peptides were derived from 
MHC molecules. A few peptides derived from exogenous bo- 
vine serum proteins were also bound to the DKBI*0401  al- 
lele. Fig. 4, c and d shows the results of the screening of two 
of the above mentioned  proteins  using our scoring  system. 
In  each case the identified  peptide is one of the  sequences 
with scores higher than 2. This methodology and its predic- 
tive potential  could  now be used to  identify  the  naturally 
processed and presented  peptides  from  potentially  autoim- 
munogenic proteins restricted by disease-linked class II MHC 
molecules. An interesting case could be, for example, the anal- 
ysis of potential autoantigens  in rheumatoid  arthritis,  an au- 
toimmune  disease genetically linked  to the DRBI*0401  al- 
lele (for reviews see references  20,  21). 
Figure 4.  Immunodominant T cell epitopes or naturally processed  pep- 
tides duted from DRBl*0401 molecules show high peptide scores. Four 
proteins were scanned for peptide regions with high scores: (a) human 
MBP, (b) influenza HA, (c) bovine hemoglobin ot chain (HBA), and (d) 
FILA-A2 c~ chain. Most of the pl-anchored nonamer peptides had scores 
between - 2 and 1 as expected from the distribution of scores in randomly 
sdected peptides (see Fig. 3 a), whereas only a few peptides had scores 
that correspond to high affinity  binding. Among those were Ix-prides (arrows) 
that were previously identified as immunodominant T call epitopes (a and 
b) or as naturally processed peptides eluted from the DRBl*0401 mole- 
cule (c and d): MBP 91-99 (arrow, a), HA 309-317 (arrow, b), HBA 33-41 
(arrow, c), and HLA-A2 58-66 (arrow, d). 
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